|6. Switch to an IL-17i over a different OSM (PICO 25)|Low (79–87, 89–95)|
|Conditional recommendation based on low-quality evidence; may consider switching to a different OSM if the patient prefers an oral versus parenteral therapy or in patients without evidence of severe PsA or severe psoriasis.| |
|7. Switch to an IL-17i biologic over an IL-12/23i biologic (PICO 18)|Moderate (87, 89–95, 98–100, 106, 107)|
|Conditional recommendation based on moderate-quality evidence; may consider an IL-12/23i biologic if the patient has concomitant IBD or prefers less frequent drug administration.| |
|8. Switch to an IL-17i biologic over abatacept (PICO 69)|Low (89–95, 103, 104)|
|Conditional recommendation based on low-quality evidence; may consider abatacept in patients with recurrent or serious infections.| |
|9. Switch to an IL-17i biologic over tofacitinib (PICO 78)|Low (89–95, 105)|